Arif Hussain

Arif Hussain, MD, is a tenured Professor of Medicine at the University of Maryland School of Medicine with secondary appointments in Pathology and Biochemistry & Molecular Biology. As Co-Leader of the Hormone Responsive Cancers Program and the Translational Working Group at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC), he bridges clinical and translational research in prostate cancer.

• BS in Mathematics, Howard University (1976)
• MD in Medicine, Howard University (1980)
• Internal Medicine Residency, Washington Hospital Center (1983)
• Hematology/Oncology Fellowship, University of Maryland Cancer Center (1986)

His research spans three decades in prostate cancer biology and clinical translation:

• Mechanisms of drug resistance with focus on Ca2+ transport ATPase and P-glycoprotein regulation
• Optimizing multimodal therapies through preclinical models (SCID/TRAMP mice)
• Population-based disparities research using SEER-Medicare datasets
• Investigator-initiated clinical trials in castration-sensitive and resistant prostate cancer
• Editorial leadership as Section Editor of Current Opinion in Oncology

His work has produced seminal findings on:

• Thapsigargin resistance hotspots in ATPase
• Neuroendocrine differentiation post-therapy in TRAMP models
• Health service disparities in elderly cancer patients
• Synergistic effects of telomere/microtubule targeting

Scientific contributions include:

• NIH KO8 Award for drug resistance research
• First to characterize thapsigargin-resistant prostate cancer models
• Key insights into therapy-induced neuroendocrine carcinomas

As a federal grant recipient for over 20 years, he has mentored through collaborative trials with Dana-Farber Cancer Institute and national cooperative groups while leading translational initiatives at UMGCCC.